Edgewise Therapeutics, Inc. EWTX

Edgewise Therapeutics (EWTX) could benefit from EDG-7500's differentiated drug profile, a potentiall

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that it will host an investor conference call to discuss the preclinical pharmacologic profile of EDG-7500, a first-in-class cardiac sarcomere modulator targeting the RLC. Data will be provided supporting EDG-7500's ability to improve cardiac relaxation while preserving overall systolic performance. Furthermore, early clinical observations in patients

UTHR, NMRA, and EWTX are drawing attention from options bears

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while preserving sys

Recently published Hypertrophic Cardiomyopathy Market Insights report includes a comprehensive understanding of current treatment practices, hypertrophic cardiomyopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights.

How Edgewise Therapeutics Stock Has Been Trading Recently Edgewise Therapeutics (EWTX) has drawn investor attention after a period of mixed short term trading, with the stock down 2.4% over the past day but higher over the past month and past 3 months. Shares last closed at US$38.81, with the company’s total return up about 63% year to date and a much larger gain over the past year. These figures prompt closer scrutiny of what is currently priced into the stock. See our latest analysis for...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced the successful completion of its previously announced definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, acquired sevasemten and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate

Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (Nasdaq: EWTX), for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments. This announcement follows regulatory clearance and customary closing conditions.

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on June 30, 2026, Edgewise granted inducement stock options to purchase a total of 16,500 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incent

Is EWTX a good stock to buy? We came across a bullish thesis on Edgewise Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on EWTX. Edgewise Therapeutics, Inc.’s share was trading at $38.83 as of June 23rd. Edgewise Therapeutics is positioned as a high-conviction clinical-stage biotech transitioning into a substantially […]